United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2001_register
executive
2010-09-24
article
Guidance for Industry on Levothyroxine Sodium; Questions and Answers; Availability
Notices
D09002ee1bdf91f46
D09002ee1bdf91ffc
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
Food and Drug Administration
originator
org
United States Government Agency or Subagency
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ``Levothyroxine Sodium: Questions and Answers.'' The guidance is intended to answer questions concerning applications for orally administered levothyroxine sodium drug products.
66 FR 13935
https://www.govinfo.gov/app/details/FR-2001-03-08/01-5609
01-5609
fr08mr01-93
4160-01-F
Docket No. 99D-2636
https://www.govinfo.gov/app/details/FR-2001-03-08/01-5609
https://www.govinfo.gov/content/pkg/FR-2001-03-08/html/01-5609.htm
https://www.govinfo.gov/content/pkg/FR-2001-03-08/pdf/01-5609.pdf
1 p.
13935
13935
66 FR 13935
Guidance for Industry on Levothyroxine Sodium; Questions and Answers; Availability; Federal Register Vol. 66, Issue
NOTICE
01-5609
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. 99D-2636
4160-01-F
01-5609
Notice.
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ``Levothyroxine Sodium: Questions and Answers.'' The guidance is intended to answer questions concerning applications for orally administered levothyroxine sodium drug products.
Submit written comments on agency guidances at any time.
Christine F. Rogers, Center for Drug Evaluation and Research (HFD 7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301 594 2041.
Reports and guidance documents; availability, etc.:
Levothyroxine sodium: questions and answers,
http://www.fda.gov/cder/guidance/index.htm
Federal Register
Vol. 66, no. 46
Office of the Federal Register, National Archives and Records Administration
2001-03-08
continuing
daily
deposited
born digital
241 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2001-03-08
P0b002ee180a0bea9
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr08mr01
https://www.govinfo.gov/app/details/FR-2001-03-08
https://www.govinfo.gov/content/pkg/FR-2001-03-08/pdf/FR-2001-03-08.pdf
https://www.govinfo.gov/content/pkg/FR-2001-03-08/xml/FR-2001-03-08.xml
fdlp
13839
14070
DGPO
2010-09-24
2023-05-05
FR-2001-03-08
machine generated
eng
FR
FR-2001-03-08
66
46